Detalle Publicación

ARTÍCULO

Proactive and systematic multidimensional needs assessment in patients with advanced cancer approaching palliative care: a study protocol

Autores: Pergolizzi, D.; Crespo, I.; Balaguer, A.; Monforte-Royo, C.; Alonso-Babarro, A.; Arantzamendi Solabarrieta, María; Belar Beitia, Alazne; Centeno Cortés, Carlos; Goni-Fuste, B.; Julià-Torras, J.; Martínez García, Marina; Mateo-Ortega, D.; May, L.; Moreno-Alonso, D.; Nabal-Vicuña, M.; Noguera Tejedor, Antonio Luís; Pascual, A.; Pérez-Bret, E.; Rocafort, J.; Rodríguez-Prat, A.; Rodriguez, D.; Sala, C.; Serna, J.; Porta-Sales, J.
Título de la revista: BMJ OPEN
ISSN: 2044-6055
Volumen: 10
Número: 2
Páginas: e034413
Fecha de publicación: 2020
Resumen:
We aim to design and evaluate a proactive and systematic method for the needs assessment using quality guidelines for developing complex interventions. This will involve patients, their relatives and healthcare professionals in all phases of the study and its communication to offer clinical practice a reliable approach to address the palliative needs of patients. Methods and analysis To design and assess the feasibility of an evidence-based, proactive and systematic Multidimensional needs Assessment in Palliative care (MAP) as a semistructured clinical interview guide for initial palliative care encounter/s in patients with advanced cancer. This is a two-phase multisite project conducted over 36 months between May 2019 and May 2022. Phase I includes a systematic review, discussions with stakeholders and Delphi consensus. The evidence gathered from phase I will be the basis for the initial versions of the MAP, then submitted to Delphi consensus to develop a preliminary guide of the MAP for the training of clinicians in the feasibility phase. Phase II is a mixed-methods multicenter feasibility study that will assess the MAP¿s acceptability, participation, practicality, adaptation and implementation. A nested qualitA nested qualitative study preliminary clues about the benefits and barriers of the MAP. The evidence gathered from phase II will build a MAP user guide and educational programme for use in clinical practice.